Enhanced Adjuvanticity of a Personal Neoantigen Vaccine Generates Potent Neoantigen-Specific Immunity
Demographics (2)
- AGE - Age of subject (phv00560115.v1.p1)
- SEX - Biological sex (phv00560111.v1.p1)
Disease Events (4)
- HISTOLOGICAL_TYPE - Disease histology (phv00560125.v1.p1)
- IS_TUMOR - Tumor status (phv00560123.v1.p1)
- PRIMARY_TUMOR_LOCATION - Location of primary tumor if applicable (phv00560127.v1.p1)
- TUMOR_STAGE - Stage of tumor if applicable (phv00560128.v1.p1)
Race and Ethnicity (1)
- RACE - Race of subject (phv00560117.v1.p1)
Other (14)
- ANALYTE_TYPE - Analyte type (phv00560120.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00560119.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00560110.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary or metastatic tumor if applicable (phv00560126.v1.p1)
- SAMPLE_ID - Sample ID (phv00560118.v1.p1)
- SAMPLE_ID - Sample ID (phv00560113.v1.p1)
- SAMPLE_TIMEPOINT - Sample collection timepoint (phv00560124.v1.p1)
- SEQUENCING_CENTER - Sequencing center (phv00560129.v1.p1)
- SEQUENCING_TECH - Sequencing tech (phv00560121.v1.p1)
- SUBJECT_ID - Subject ID (phv00560114.v1.p1)
- SUBJECT_ID - Subject ID (phv00560109.v1.p1)
- SUBJECT_ID - Subject ID (phv00560112.v1.p1)
- THERAPEUTIC_RESPONSE - Response to therapy (phv00560116.v1.p1)
- TREATMENT - Treatment (phv00560122.v1.p1)